Drug Target Review

DECEMBER 27, 2023

This interaction inhibits inflammation and immune activation, and in particular prevents macrophages from phagocytosing and destroying cancer cells. By blocking CD24 with an antibody drug, our goal is to powerfully reactivate the anti-cancer immune response and drive therapeutic efficacy.

Immune Response 105

Immune Response Science Clinical Development Drugs 105

The Pharma Data

JANUARY 25, 2021

The cocktail reduced viral load “with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline,” the researchers said. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group.

Immune Response 52

Immune Response Treatment Clinical Trials Hospitals 52

The Pharma Data

AUGUST 6, 2020

Under the pact, AZ will transfer the vaccine’s technology to BioKangtai, which will in return reserve enough capacity to make at least 100 million doses of the shot by the end of 2020 and expand to 200 million doses per year by the end of 2021. Financial terms were not disclosed. Before the BioKangtai tie-up, it promised to provide the U.S.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

JANUARY 22, 2021

The Weinreich article also reports that the “antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group.”.

Immune Response 52

Immune Response Clinical Trials Hospitals Trials 52

The Pharma Data

DECEMBER 12, 2020

Sanofi and GlaxoSmithKline (GSK) have decided to push back the phase 2b trial of their adjuvanted COVID-19 vaccine after finding it produced only a weak immune response in older patients, delaying the potential delivery of a vaccine that could contribute to the mass vaccination effort in the U.S. to vaccinate on demand. James Miessler.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Immune response was measured using immunoglobulin G (IgG) assays. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

JANUARY 19, 2021

With this kind of a start, 2021 may be scorching. The company is working on a new approach to immunotherapy that uses the body’s own T-cells to create specific, potent, and durable immune responses for cancer and other life-threatening immune-mediated disease. TCR2 Therapeutics – The Cambridge, Mass.

Small Molecule 52

Small Molecule Trials Laboratories Immune Response 52

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. FDA for ITP.

Therapies 52

Therapies Pharmacokinetics Treatment RNA 52

The Pharma Data

APRIL 15, 2022

In December 2021, Pfizer and BioNTech announced the companies would test a third 3 µg dose given at least two months after the second dose in children under age 5 and a third dose of the 10 µg formulation in children 5 to under 12 years of age. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ).

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

DECEMBER 20, 2020

In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. The company, along with partners University of Nottingham and Trent University, received a British government grant to support the study. .

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. If results are positive, Phase 3 study to start in Q2 2021, with vaccine expected to be available in Q4 2021. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

JANUARY 31, 2021

1, 2021 12:05 UTC. Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). ATLANTA–( BUSINESS WIRE )– Virios Therapeutics, Inc.

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

JANUARY 9, 2021

9, 2021 — A task force of allergists and immunologists recommends those administering the COVID-19 vaccine ask patients some key questions beforehand. But such patients should be warned of the possibility that they will have a lower immune response. © 2021 HealthDay. . © 2021 HealthDay. Posted: January 2021.

Vaccine 52

Vaccine Immune Response Doctors Disease 52

The Pharma Data

DECEMBER 8, 2020

With the proceeds, Qu Biologics will complete stage 1 of the RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease and its Phase 2 Study to assess activation of anti-cancer immune response in colon cancer. “We

Immune Response 52

Immune Response Clinical Trials Disease Trials 52

The Pharma Data

JANUARY 5, 2021

5, 2021 — Stem cells derived from a baby’s umbilical cord can help save the lives of the sickest COVID-19 patients, results from a small new clinical trial suggest. © 2021 HealthDay. Posted: January 2021. TUESDAY, Jan. “The results are quite spectacular,” said senior researcher Dr. .”

Immune Response 52

Immune Response Hospitals Clinical Trials Trials 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. The company will work with Medsafe, New Zealand’s regulatory agency, to obtain product approvals as needed. About Novavax.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. 21, 2021, online.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

The Pharma Data

SEPTEMBER 2, 2020

The randomised, double blind and placebo-controlled trial is designed to evaluate the safety, reactogenicity (tolerability) and immunogenicity (immune response) of the experimental COVID-19 vaccine candidate. If successful, the companies intend to request regulatory approval in the first half of 2021.

Vaccine 52

Vaccine Trials Immune Response Clinical Trials 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. About Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon. Jason Scott. Source link.

Vaccine 52

Vaccine Immune Response Clinical Trials Trials 52

The Pharma Data

JANUARY 12, 2021

Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It It is a new immune checkpoint that is expressed on three different immune cells: Macrophages, [Natural Killer] NK cells, and T cells. [It]

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

JUNE 26, 2021

JUNE 22 , 2021. About the Phase 1 trial The US-based Phase 1 clinical trial will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) mRNA-based flu vaccine candidate in up to 280 participants. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 25, 2021

CureVac and GSK expect to progress the second-generation vaccine candidate into clinical testing in the third quarter of 2021, with the goal of introducing the vaccine in 2022, subject to regulatory approval. In February 2021, CureVac initiated a rolling submission with the European Medicines Agency (EMA) for CVnCoV. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 23, 2020

Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021. Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com. About TREM-1 pathway.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum in the first half of 2021.

Vaccine 52

Vaccine Immune Response Virus RNA 52

PerkinElmer

MAY 6, 2022

One approach currently being explored involves stimulating innate immune response pathways. For example, the STimulator of InterferoN Genes (STING) pathway, which is known to play a critical role in innate immunity in response to viral and bacterial DNA, has also been shown to promote anti-tumor immune responses.

Immune Response 52

Immune Response DNA Clinical Trials Clinical Development 52

The Pharma Data

SEPTEMBER 30, 2021

Our results show that the candidate vaccine formulation is safe, produces rapid immune responses – within seven days – and elicits comprehensive immunity against SARS-CoV-2,” said Varadarajan. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. CHENGDU, China , Feb. These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.”

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

NOVEMBER 27, 2020

The RDIF has begun production of the vaccine abroad, partnering with pharmaceutical companies to produce vaccines for 500 million people per year starting in January 2021. RDIF claimed deliveries of the Russian Sputnik V vaccine would be made to customers in January 2021 based on existing partnerships with foreign manufacturers.

Vaccine 52

Vaccine Virus International Immune Response 52

The Pharma Data

JANUARY 21, 2021

The 2021 trend of biotech initial public offerings (IPOs) continued this week. On January 5, 2021, the U.S. The company is working on a new approach to immunotherapy that uses the body’s own T-cells to create specific, potent, and durable immune responses for cancer and other life-threatening immune-mediated disease.

Immune Response 52

Immune Response Laboratories Trials Therapies 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer?BioNTech Procedures should be in place to avoid injury from fainting. BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

AUGUST 15, 2021

Melody Swartz, Jeffrey Hubbell and colleagues had previously developed a vaccine delivery tool called polymersomes – self-assembling, spherical nanoparticles that can encapsulate antigens and adjuvants (helper molecules that boost the immune response) and then release them inside immune cells. 2021 Apr 8:2021.04.08.438884.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

The Pharma Data

AUGUST 16, 2021

Pfizer and BioNTech plan to seek licensure of the third dose via a supplemental Biologics License Application (BLA) in individuals 16 years of age and older, pending FDA approval of the primary BLA submitted in May 2021. today announced that they have submitted Phase 1 data to the U.S. In the U.S.,

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

JANUARY 18, 2021

Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. 19, 2021 /PRNewswire/ — Neurophth Therapeutics, Inc. , Use of AAVnerGene capsid library provided to Neurophth for ophthalmic gene therapy.

Therapies 52

Therapies Immune Response DNA Treatment 52

The Pharma Data

NOVEMBER 23, 2020

After vaccination, the cells produce the spike protein, stimulating the immune system to attack the SARS-CoV-2 virus. Likely EUA Date: Possibly January 2021, but unclear in the U.S. Interim results from its Phase I/IIa trial demonstrated a single dose of the vaccine induced a robust immune response and was generally well-tolerated.

Vaccine 52

Vaccine Virus Immune Response Trials 52